
Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments - 2
Finding the Universe of Computer generated Reality: Individual Encounters - 3
‘Aid for Ukraine’ pierogi fundraiser event - 4
Joshua Made Last-Second Seat Change That Saved His Life - 5
Find Your Internal Culinary expert: Cooking Strategies and Recipes
Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
She just became the first wheelchair user to travel to space
Inside the alleged Russian operation to trigger anti-government protests in Angola
Figure out How to Assess the Unwavering quality of SUVs for Seniors
Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
Was This Driver Simply Having Some good times Or Behaving Like An Ass?













